Vivus weight-loss treatment Qsymia wins FDA nod

The FDA cleared Vivus' weight-loss treatment Qsymia, a combination of anti-seizure drug topiramate and generic weight-loss treatment phentermine, for obese adults or overweight adults with high cholesterol, diabetes or hypertension. The drug is the second weight-loss treatment approved by the FDA after 13 years without approvals.

View Full Article in:

New York Times (tiered subscription model), The · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX